Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

t on Non GAAP basis.

The following items are included in Adjustments:

a)Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($31.2 million), impairment charges to record DAYTRANA assets at fair value less costs to sell ($42.7 million) and tax effect of adjustments;

b)Acquisitions and integration activities: Upfront payment to Acceleron ($45.0 million), acquisition costs are principally costs associated with the acquisition of Movetis ($5.8 million) and tax effect of adjustments;

c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($6.2 million) and dual running costs ($1.1 million) on the transfer of manufacturing from Owings Mills and reorganization costs ($9.7 million) on the transfer of manufacturing from Owings Mills and establishment of an international commercial hub in Switzerland, and tax effect of adjustments; and

d)Depreciation: Depreciation of $22.8 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


 

Unaudited results for the nine months to September 30, 2011

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquis Divestments, Amorti itions & reorgan September -zation integr -izations & Reclas September 9 months to, 30, & asset -ation discontinued -sify 30, 2011 impairments activ operations deprec 2011 -ities -iation (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 3,121.2 - - - - 3,121.2 Costs and expenses: Cost of product sales 434.7 - (9.0) (9.0) (22.4) 394.3 Research and development 556.3 (16.0) - - (16.4) 523.9 Selling, general and administrative 1,295.3 (119.1) - - (46.4) 1,129.8 Loss on sale of product rights 3.8 - - (3.8) - - Reorganization costs 18.0 - - (18.0) - - Integration & acquisition costs 7.9 - (7.9) - - - Depreciation
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... addition of the "Bone Morphogenetic Proteins Market ... Trauma, Reconstructive and Oral - Maxillofacial) - Global ... 2014 - 2022" report to their offering. ... is studied based on the types of recombinant ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
(Date:5/20/2015)... 20, 2015  HOSTING, the leading provider of ... is an official partner of the College ... Members Services Program. This unique collaboration leverages ... services and best practices derived from the ... service providers, enabling member healthcare organizations to ...
Breaking Biology Technology:Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... - Researchers are developing a new type of computer ... memory and use far less power than flash memory ... "ferroelectric" polymer, a material that switches polarity when electric ... ferroelectric transistor. "It,s in a very nascent stage," ...
... Renmatix , the leading producer of ... company,s commercial approach to producing sugars more cheaply ... industrial sugars, the foundation of the emerging bioindustrial ... fuels and chemicals to cost-effective biobased alternatives. ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... announced that it retired its remaining secured 9% Notes ... principal amount of unsecured 5.5% Notes outstanding. ... principal amount of its 9% Notes, the Company paid ...
Cached Biology Technology:New 'FeTRAM' is promising computer memory technology 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 3Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... better way to predict earthquakes and avalanches may soon ... at NJIT. Using mathematical modeling, researchers are ... "Computational Homology, Jamming and Force Chains ... Foundation grant has been awarded to Louis Kondic, associate ...
... taskswould have smiled at one of leptin,s mechanisms for curbing ... enlists the sympathetic nervous system to prevent bone-making cells from ... The study will appear online December 22, 2008 ( ... of The Journal of Cell Biology ( JCB ...
... Clive Svendsen,s lab dishes, he couldn,t have been more ... lost in patients with the devastating neurological disease spinal ... stem cell biologist had recreated the hallmarks of a ... from a patient. By allowing scientists the unparalleled ...
Cached Biology News:To improve forecasting earthquakes, NJIT mathematician studies grains 2Leptin's long-distance call to the pancreas 2Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (Z71,517-4) or contact customer ... polystyrene (expanded surface, easy grip) ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
Biology Products: